FATTAL Elias

Equipe 5 : Ingénierie particulaire et cellulaire à visée thérapeutique

 : elias.fattal[a]u-psud.fr

 : +33.1 46 83 55 82

 : +33.1 46 83 59 46

Bureau : Tour D5 / 223

Page personnelle

CV

Elias Fattal est Professeur de Pharmacotechnie à la Faculté de Pharmacie Châtenay-Malabry au sein de l’Université Paris-Sud. Il a présidé l’APGI de 2003 à 2010 et dirige l'Institut Galien Paris-Sud depuis 2010. Elias Fattal est titulaire du diplôme d’état de Docteur en pharmacie (1983), a obtenu le diplôme de Docteur de l’Université Paris-Sud en 1990 et a été pendant 2 années (1990- 1991) chercheur invité à l’Université de Californie, San Francisco aux USA. Le professeur Fattal est l'auteur de plus de 260 articles à comité de lecture. Il a déposé 14 brevets internationaux et a reçu le Pharmaceutical Sciences World Congress Research Achievement (2007), the controlled Release Society fellow Award (2016). Il a enfin été récompensé en 2016 par l'Académie des sciences (Prix du Dr et de Mme Henri Labbé) et a reçu le prix Maurice-Marie Janot en 2018. Il est membre du comité de rédaction de plusieurs revues scientifiques.

Elias Fattal is professor of drug delivery sciences at the faculty of Pharmacy of University Paris-Sud. He has been President of APGI from 2003 to 2010 and is heading the Institut Galien Paris-Sud since 2010. Elias Fattal has received his Pharmacy Degree (1983) and Ph.D. (1990) from the University of Paris-Sud. After visiting the University of California San Francisco for a post-doctoral position (1990-1991), he became associate (1992) and full Professor at the University of Paris-Sud (2000). Prof. Fattal has authored more than 260 refereed articles. He has issued 14 international patents and has received the Pharmaceutical Sciences World Congress Research Achievement (2007), the controlled Release Society fellow Award (2016) and was awarded in 2016 by the French Academy of Sciences (Prix du Dr et de Mme Henri Labbé) and has received the "Maurice-Marie Janot" award in 2018. He serves in the editorial board of several scientific journals.

Mots clés

Administration pulmonaire, acides nucléiques, inflammation, cancer, aptamères, nanotoxicologie

Lung delivery, nucleic acids, inflammation, cancer, aptamers, nanotoxicology

10 publications majeures

• Costamagna F, Hillaireau H, Vergnaud-Gauduchon J, Clarisse D, Jamgotchian L., Loreau O, Denis S, Gravel E, Doris E, Fattal E. Nanotoxicology at the particle/micelle frontier: influence of core-polymerization on the intracellular distribution, cytotoxicity, and genotoxicity of polydiacetylene micelles. Nanoscale 2020, 12, 2452-2463.
• Lorscheider M., Tsapis N., Ur-Rehman M., Gaudin F., Stolfa I., Abreu S., Mura S., Chaminade P., Espeli M., Fattal E., Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis. Journal of Controlled Release 2019, 296 179-189.
• Alshaer, W, Hillaireau H, Vergnaud J, Mura S, Deloménie C, Sauvage F, Ismail S, Fattal E. Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model. J Control Release 2018, 271:98-106.
• Alshaer W., Hillaireau H., Fattal E., Aptamer-guided nanomedicines for anticancer drug delivery. Advanced drug delivery reviews, 2018, 134, 122-137.
• Bohr A, Tsapis N, Andreana I, Chamarat A, Foged C, Delomenie C, Noiray M, El Brahmi N, Majoral JP, Mignani S, Fattal E. Anti-inflammatory effect of anti-TNF-a siRNA cationic phosphorous dendrimers nanocomplexes administered intranasally in a murine acute lung injury model. Biomacromolecules 2017, 18(8):2379–2388.
• Ruge C, Hillaireau H, Grabowski N, Beck-Broichsitter M, Canadas O, Tsapis N, Casals C, Nicolas J, Fattal E. Pulmonary surfactant protein a – mediated enrichment of surface-decorated polymeric nanoparticles in alveolar macrophages. Molecular Pharmaceutics 2016, 13(12):4168-4178.
• Dosio F, Arpicco S, Stella B, Fattal E. Hyaluronic acid for anticancer drug and nucleic acid delivery Advanced Drug Delivery Reviews 2016, 97:204–236.
• Santiago L, Hillaireau H, Grabowski N, Mura S, Nascimento T, Dufort S, Coll J-L, Tsapis N, Fattal E. Compared in vivo toxicity in mice of lung delivered biodegradable and non-biodegradable nanoparticles. Nanotoxicology 2016, 10(3):292-302.
• Grabowski N, Hillaireau H, Vergnaud J, Nicolas V, Tsapis N, Kerdine-Romer S, Fattal E. Surface-modified biodegradable nanoparticles’ impact on cytotoxicity and inflammation response on a co-culture of lung epithelial cells and human-like macrophages Journal of Biomedical Nanotechnology. 2016, 12:135-146.
• Ruge C, Bohr A, Beck-Broichsitter M, Nicolas V, Tsapis N, Fattal E. Disintegration of nano-embedded microparticles after deposition on mucus: a mechanistic study. Colloids and Surfaces B: biointerfaces 2016, 139:219–227.
• Leite Nascimento T, Hillaireau H, Vergnaud J, Fattal E. Lipid based nanosystems for CD44 targeting in cancer treatment: recent significant advances, ongoing challenges and unmet needs. Nanomedicine 2016, 12(1):135-46.
• Nascimento T.L, Hillaireau H, Fattal E. Noiray M., Bourgaux C., Arpicco S., Pehau-Arnaudet G., Taverna M., Cosco D., Tsapis N., Fattal E. Supramolecular organization and siRNA binding of hyaluronic acid-coated lipoplexes for targeted delivery to CD44 receptor. Langmuir 2015, 31(41):11186-11194.